<DOC>
	<DOCNO>NCT00686699</DOCNO>
	<brief_summary>This study design determine preladenant ( SCH 420814 , MK-3814 ) reduce drug-induced involuntary movement participant schizophrenia schizoaffective disorder . Participants evaluate two 14-day treatment period 3-week washout period treatment period . The primary outcome measure , Extrapyramidal Symptom Rating Score ( ESRS ) , evaluate frequently treatment period .</brief_summary>
	<brief_title>Study Preladenant Treatment Antipsychotic Induced Movement Disorders Participants With Schizophrenia ( Study P04628 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Dyskinesia , Drug-Induced</mesh_term>
	<mesh_term>Akathisia , Drug-Induced</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Males female &gt; =18 &lt; =65 year old body mass index 1731 kg/m^2 . Diagnosed Diagnostic Statistical Manual Mental Disorders , 4th Ed . ( DSMIV ) criterion schizophrenia/schizoaffective ( depressive type ) disorder antipsychoticinduced extrapyramidal symptom ( parkinsonism , akathisia , dystonia , tardive dyskinesia [ TD ] ) base follow ESRS criterion : parkinsonism , dystonia , TD ESRS score &gt; =2 2 item &gt; =3 one item , akathisia ESRS score &gt; =3 two item , Has total ESRS score &gt; 8 . Must receive neuroleptic stable dosage least 7 day prior enrollment . Clinical laboratory test , physical exam , electrocardiogram must within normal limit clinically acceptable investigator/sponsor ( except sign symptom Schizophrenia/Schizoaffective disorder ) . Liver function test must within normal limit screen . Participant screen drug high potential abuse must negative . Must free clinically significant disease schizophrenia/schizoaffective disorder would interfere study evaluation procedure . Must level understand sufficient communicate research staff , cooperate protocol require test examination , able adhere protocol restriction schedule . Must able understand nature study must willing sign inform consent ( required patient patient 's authorized legal representative ) prior study enrollment . Females must follicle stimulate hormone ( FSH ) &gt; =40 lU/L great 12 month since last menses surgically sterilize . Has history clinically significant local systemic infectious disease within 4 week prior initial treatment administration , clinically significant food drug allergy , seizure , alcohol/drug dependence , previous neurosurgery , coronary artery disease ( include myocardial infarction [ MI ] , cerebrovascular disease [ stroke , transient ischemic attack ( TIA ) ] , peripheral arterial disease ) . Has participate clinical trial investigational drug within 60 day donate blood within precede 90 day prior start study . Has circulate human immunodeficiency virus ( HIV ) , hepatitis C antibody , hepatitis B surface antigen . Is allergic preladenant ( SCH 420814 , MK3814 ) excipients preladenant capsule ( citric acid , lactose monohydrate , croscarmellose sodium , magnesium stearate [ nonbovine , vegetable grade ] , Food , Drug , Cosmetic [ FD &amp; C ] blue , titanium dioxide , gelatinnational formulary [ NF ] ) . Females surgically sterilize postmenopausal . Males sexually active agree use barrier method birth control study . Has severe/uncontrolled hypertension . ( Participants hypertension well control stable dose standard antihypertensive medication least 4 week randomization eligible . ) Has atrioventricular ( AV ) block , sick sinus syndrome , congestive heart failure , participant electrocardiograms ( ECGs ) consistent ischemic heart disease , significant Q wave . Has DSMIV criterion dementia ( except due schizophrenia/and schizoaffective disorder ) , individual opinion investigator able understand comply study procedure instruction staff socially incapable participate study . Does comply requirement participant use drug ( except acetaminophen allow medication ) within 2 week prior study , alcohol ( wine , beer ) within 72 hour prior drug administration . Judged clinically suicidal risk serious include study . Has receive electroconvulsive therapy within 30 day randomization . Is currently take clozapine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Anti-Dyskinesia Agents</keyword>
	<keyword>Antipsychotic Agents</keyword>
</DOC>